Akari Therapeutics, Plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Akari Therapeutics, Plc
Biopharma Excellence recently convened three experts in the world of rare disease in a roundtable to discuss the emerging approaches to data collection when patient populations are very small. Their discussion has been summarized for In Vivo.
Promising pivotal data boost chances for Omeros’ narsoplimab to become a highly needed, first-to-market drug for the treatment of a deadly complication of stem cell transplants.
Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.
The latest drug development news and highlights from our US FDA Performance Tracker.
- Other Names / Subsidiaries
- Celsus Therapeutics plc
- Morria Biopharmaceuticals, plc
- Volution Immuno Pharmaceuticals SA
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.